Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
This new facility strengthens Latin America as a collaborative hub
Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training
IKS Health's innovative solution orchestrates a roll out of critical operations functions into a unified and efficient connected workflow
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
Subscribe To Our Newsletter & Stay Updated
